14/09/2026
๐ Exciting Progress at HA TECH
We are excited to share continued progress across our diagnostic portfolio, with several products already holding regulatory certification and a growing pipeline of innovative molecular and rapid diagnostic solutions advancing towards CE-IVDR certification. These developments reflect our commitment to delivering high-quality Australian-developed diagnostics to healthcare providers and patients around the world
๐งฌ Diagnostic Portfolio
RT-PCR Molecular Diagnostics โข respiratory disease panels including COVID-19, Influenza A/B, RSV, Adenovirus, Rhinovirus, Metapneumovirus, Parainfluenza, and Bordetella species.
โข STI testing for Chlamydia, Gonorrhoea, Syphilis, Mpox, Herpes Simplex Virus, and other sexually transmitted infections.
โข Mosquito-borne disease detection for Malaria, Dengue, Chikungunya, and Zika.
โข Cancer screening assay for prostate cancer and womenโs health in HPV detection.
โก Rapid Antigen & Antibody Tests โข Respiratory infection testing, including COVID-19, Influenza, and RSV.
โข Infectious disease testing for HIV, Hepatitis, Syphilis, Dengue, and Malaria.
โข Women's health (Chlamydia & Gonorrhoea detection), UTI, and fertility testing.
โConvenient point-of-care and self-testing solutions designed to expand healthcare accessibilityโ
๐ Biotherapeutics Pipeline
Our Biotherapeutics Division continues to advance its biosimilar portfolio, with Semaglutide (Ozempicยฎ biosimilar) and Insulin Glargine (Lantusยฎ biosimilar) programs progressing towards clinical trials.
At HA TECH, we remain committed to our mission of "Superior Detection for a Safer World", delivering innovative diagnostics and accessible therapies that improve patient outcomes worldwide.